PD-1 Knockout Engineered T Cells for Advanced Lung Adenocarcinoma with PDL-1 high expression

A Phase II Trial of PD-1 Knockout Engineered T Cells for the Treatment of Advanced Lung Adenocarcinoma with PDL-1 high expression progressed after multi-line treatment

Status

Active, not recruiting

Phases

Phase 2

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-OIC-17010389

Enrollment

Unknown

Registered

2017-01-11

Start date

2017-01-16

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced Lung Adenocarcinoma with PDL-1 high expression

Interventions

experimental group :PD-1 Knockout Engineered T Cells

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Stage III/B or IV lung adenocarcinoma with PDL-1 high expression; 2. Measurable disease; 3. Progressed after all standard treatment; 4. ECOG performance status of 0-2; 5. Expected life span: >= 3 months; 6. Toxicities from prior treatment has resolved. Washout period is 4 weeks for chemotherapy, and 2 weeks for targeted therapy; 7. Major organs function normally; 8. Women at pregnant ages should be under contraception; 9. Hematologic studies satisfy the following requirements within 1 week before treatment WBC=3×10^9/L; ANC=1.5×10^9/L; Hb=80g/L;

Exclusion criteria

Exclusion criteria: 1. Pathology is not lung adenocarcinoma,or without PDL-1 high expression; 2. Emergent treatment of tumor emergency is needed; 3. Poor vasculature; 4. Coagulopathy, or ongoing thrombolytics and/or anticoagulation; 5. Blood-borne infectious disease, e.g. hepatitis B; 6. History of mandatory custody because of psychosis or other psychological disease inappropriate for treatment deemed by treating physician; 7. With other immune diseases, or chronic use of immunosuppressants or steroids; 8. Compliance cannot be expected; 9. Other conditions requiring exclusion deemed by physician.

Design outcomes

Primary

Measure	Time frame
Number of participants with Adverse Events and/or Dose Limiting Toxicities as a Measure of Safety and tolerability of dose of PD-1 Knockout T cells using Common Terminology Criteria for Adverse Events (CTCAE v4.0) in patient;	—

Secondary

Measure	Time frame
Response Rate;Progression free survival (PFS);Progression free survival (PFS);Overall Survival (OS;Peripheral blood circulating tumor DNA;Temporal Interleukin-2 change in the peripheral blood;Temporal Interferon-? change in the peripheral blood;	—

Countries

China

Contacts

Public ContactYueyin Pan

Anhui Province Hospital

yueyinpan1965@163.com+86 13805695536

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026